TB-500 is a synthetic fragment of thymosin beta-4. The human trial literature covers full-length TB4 in dermal wound and dry-eye studies, not the fragment sold as a research reagent, so the two evidence bases should be read separately.
Read this first
Every figure on this page is a range reported in published literature or in a publicly documented study protocol. It is a record of what researchers used, not a recommendation, a therapeutic protocol, or advice. Peptide Intel Hub is an independent publication, sells nothing, and describes these compounds as in-vitro research reagents only.
Compound at a glance
Class
Actin-sequestering peptide fragment
Reported half-life
Reported around 2 hours for the parent thymosin beta-4 in circulation
Routes used in the literature
Subcutaneous and intraperitoneal in published animal work; intravenous in early human trials of full-length TB4
Also written as
Thymosin Beta-4 fragment
What the published studies reported
Each row below describes one body of work. The model and population are part of the figure — a rodent per-kilogram quantity and a human trial quantity are not comparable.
Rodent cardiac and dermal repair models (full-length TB4)
Reported quantity
Commonly 1–10 mg/kg in rodent studies
Frequency
Daily to three times weekly depending on the model
Study duration
2–4 weeks
Cardiac studies typically use the higher end; dermal wound models the lower end.
Early-phase human trials of full-length thymosin beta-4
Reported quantity
Topical 0.01–0.1% formulations; intravenous arms reported up to 42 mg per infusion
Frequency
Topical twice daily; intravenous single or weekly
Study duration
14–28 days in the published dermal studies
These figures describe full-length TB4 as an investigational drug, not the TB-500 fragment.
Dosage chart
These figures match the published chart for this compound on peptidedosages.com, including the reconstitution volume, resulting concentration, insulin-syringe units and the staged schedule. Educational reference only — not instructions, and not medical advice.
TB-500 · 10 mg Vial
TB-500 is dosed at 500 mcg–1 mg daily via subcutaneous injection in educational protocols. A 10 mg vial reconstituted with bacteriostatic water yields about 3.33 mg/mL. This information is for research and educational use only.
Reconstitute
Add 3.0 mL bacteriostatic water → ~ 3.33 mg/mL concentration.
Typical daily range
500–1000 mcg once daily (gradual titration recommended).
Easy measuring
At 3.33 mg/mL, 1 unit = 0.01 mL ≈ 33.3 mcg on a U‑100 insulin syringe.
Storage
Lyophilized: store at −20 °C (−4 °F); after reconstitution, refrigerate at 2–8 °C (35.6–46.4 °F); do not freeze reconstituted solution.
The same arithmetic for every vial size TB-500 is supplied in, using a fixed 3 ml of bacteriostatic water. One unit on a U-100 insulin syringe is 0.01 ml, so the unit column below is simply the volume that carries the reported amount. Educational arithmetic only — not instructions, and not medical advice.
TB-500 · 3 ml bacteriostatic water
Vial size
Concentration
Per 1 unit
500 mcg =
1 mg =
2 mg
0.67 mg/ml
7 mcg
75 units
150 units
5 mg
1.67 mg/ml
17 mcg
30 units
60 units
10 mg
3.33 mg/ml
33 mcg
15 units
30 units
Unit columns use the range reported for this compound (500 mcg–1 mg). Only the vial sizes this compound is actually supplied in are shown, and every figure assumes exactly 3 ml of bacteriostatic water. For any other volume, use the reconstitution calculator.
Reconstitution maths
Research vials are typically 2 mg, 5 mg or 10 mg lyophilised. 5 mg reconstituted with 2 mL of bacteriostatic water gives 2.5 mg/mL.
Fragment and full-length peptide have different molecular weights — a milligram of one is not a milligram of the other in molar terms.
Most circulated 'weekly then maintenance' schedules trace to forums, not to published protocols.
Actin-binding peptides are studied in oncology contexts as well; the literature is not uniformly favourable.
Sources and citations
These are the published records the figures on this page are drawn from. Each one describes what researchers administered, in which model or population, and over what period. Quantities reported in a study are specific to that study's design and are not transferable guidance.
[1]
Thymosin β4 enhances the healing of medial collateral ligament injury in rat
Xu B, Yang M, Li Z, et al. · Regul Pept · 2013 · PMID 23523891
Rats with surgically induced medial collateral ligament injury received local/systemic thymosin beta-4 doses to assess effects on ligament healing.
Effects of BPC-157 and TB-500 on Achilles tendon healing in rats: A histopathological and biomechanical study
Biçer O, Adanir O, Güleryüz Y, et al. · Joint Dis Relat Surg · 2026 · DOI jointdrs.org/full-text/1851
Rats with Achilles tendon injury were treated with defined doses of TB-500 (thymosin beta-4 fragment) or BPC-157 to compare histopathological and biomechanical healing outcomes.
Peptide Intel Hub is an independent publication and has no affiliation, ownership or commercial relationship with the suppliers listed. We sell nothing and take no payments — links are editorial references only.
Share
Independent publication — we sell nothing. Supplier disclosure
Peptide Intel Hub is an independent educational publication. We are not affiliated with, owned by, or the same company as Regena Peptides and Regena.app (regena-peptides.com / regena.app). We do not sell, supply, ship or take payment for any compound. Because readers regularly ask where compounds discussed in published studies can be sourced for laboratory work, we list Regena Peptides and Regena.app as suppliers we have verified and trust — every batch is released with a lot-matched third-party certificate of analysis (HPLC purity and mass-spectrometry identity). Outbound links are marked nofollow/sponsored and are provided to help readers, not to sell.